BerGenBio
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BerGenBio is a clinical-stage biopharmaceutical company that develops innovative drugs to treat aggressive diseases, primarily cancer and severe respiratory infections. The company's research has focused on developing a pipeline of first-in-class selective AXL kinase inhibitors, with bemcentinib as its lead candidate. In mid-2025, BerGenBio announced a proposed merger with Oncoinvent, a company specializing in radiopharmaceutical cancer therapies, to combine their expertise and advance the development of new treatments.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for BerGenBio.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-20 07:00 |
Interim Report
BerGenBio First half results 2025 - Attachment: H1_2025_Financial_report.pdf
|
English | 905.6 KB | |
| 2025-08-20 07:00 |
Earnings Release
BerGenBio First half results 2025
|
English | 5.4 KB | |
| 2025-08-05 16:49 |
Share Issue/Capital Change
BerGenBio ASA - Updated key information related to the rights issue
|
English | 10.0 KB | |
| 2025-08-04 13:40 |
Post-Annual General Meeting Information
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
Norwegian | 794.1 KB | |
| 2025-08-04 13:40 |
M&A Activity
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
English | 2.2 KB | |
| 2025-07-03 14:53 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting - Attachment: BerGenBio_…
|
Norwegian | 441.1 KB | |
| 2025-07-03 14:53 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting
|
English | 2.6 KB | |
| 2025-06-30 22:30 |
Share Issue/Capital Change
BerGenBio ASA - Key information related to the rights issue
|
English | 10.0 KB | |
| 2025-06-30 22:05 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
|
English | 101.2 KB | |
| 2025-06-30 22:05 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue
|
English | 21.0 KB | |
| 2025-06-30 22:00 |
M&A Activity
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
|
English | 19.5 KB | |
| 2025-06-26 11:29 |
Post-Annual General Meeting Information
BerGenBio ASA - Minutes from the annual general meeting 2025 - Attachment: BerG…
|
Norwegian | 419.9 KB | |
| 2025-06-26 11:29 |
Post-Annual General Meeting Information
BerGenBio ASA - Minutes from the annual general meeting 2025
|
English | 1.1 KB | |
| 2025-06-03 19:22 |
M&A Activity
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
|
English | 2.6 KB | |
| 2025-06-03 15:55 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Annual General Meeting - Attachment: Notice_of_AGM_Ber…
|
Norwegian | 424.8 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
